Monographie - Tirofiban - Stabilis 4.0

Siste oppdatering :
19/11/2024

Antikoagulantia

Tirofiban

Injeksjon

Oppløsningsstabilitet

Stabilitet i blandinger

Faktorer som påvirker stabiliteten

Kompatibilitet

Administrasjonsmåte

Referanser

pdf

Handelsnavn

Handelsnavn

Handelsnavn er veiledende og sammensetning av hjelpestoffer kan være forskjellig avhengig av land og produsent

Aggrastat	Australia, Belgia, Canada, Danmark, De forente arabiske emirater, Finland, Iran, Irland, Italia, Luxembourg, Malaysia, Nederland, New Zealand, Norge, Polen, Portugal, Saudi-Arabia, Storbritannia, Sveits, Sverige, Tyrkia, Tyskland, Ungarn, USA, Østerrike
Agrastat	Argentina, Brasil, Chile, Colombia, Ecuador, Egypt, Frankrike, Marokko, Mexico, Peru, Spania, Venezuela
Thrombostat	Tyrkia
Tirofiban	Spania, Tyskland
Tiroprest	Tyrkia
Welban	Spania
Xtraban	India

Referanser

Injeksjon

Referanser : Tirofiban

	Type	publikasjon
1071	Journal	Bergquist PA, Zimmermann J, Kenney RR, Han RYH, Hunke WA. Stability of tirofiban hydrochloride in three commonly used IV solutions and polyvinyl chloride administration sets. Am J Health-Syst Pharm 1999 ; 56: 1627-1629.
1420	Journal	Bergquist PA, Hunke WA, Reed RA, Manas D, Forsyth RJ, Kenney RR, Cook J, Holahan M. Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration. J Clin Pharm Ther 1999 ; 24: 125-132.
1508	Journal	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1512	Labratorium	Tirofiban (Aggrastat®) - Summary of Product Characteristics Beacon Pharmaceuticals Ltd 2015
1600	Journal	Garabito MJ, Jimenez L, Bautista J, Santos-Rubio MD, Perez Rodrigo I. Stability of tirofiban hydrochloride in 0.9% sodium chloride injection for 30 days. Am J Health-Syst Pharm 2001 ; 58: 1850-1851.
1603	Journal	Bergquist PA, Manas D, Hunke WA, Reed RA. Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs. Am J Health-Syst Pharm 2001 ; 58: 1218-1223.
1611	Journal	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1713	Journal	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
2004	Journal	Patel K, Hursting MJ. Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 1381-1384.
3823	Journal	Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l’unité de soins intensifs Pharmactuel 2015 ; 48, 3 : 146-152.

Mentions Légales